| __timestamp | Gilead Sciences, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 59644696 |
| Thursday, January 1, 2015 | 3426000000 | 79541000 |
| Friday, January 1, 2016 | 3398000000 | 98015000 |
| Sunday, January 1, 2017 | 3878000000 | 103958000 |
| Monday, January 1, 2018 | 4056000000 | 103654000 |
| Tuesday, January 1, 2019 | 4381000000 | 128951000 |
| Wednesday, January 1, 2020 | 5151000000 | 135799000 |
| Friday, January 1, 2021 | 5246000000 | 149883000 |
| Saturday, January 1, 2022 | 5673000000 | 220206000 |
| Sunday, January 1, 2023 | 6090000000 | 265542000 |
| Monday, January 1, 2024 | 6091000000 |
Data in motion
In the competitive world of biotechnology, managing expenses is crucial for sustained growth and innovation. This analysis compares the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Gilead Sciences, Inc. and Travere Therapeutics, Inc., from 2014 to 2023.
Gilead Sciences, a leader in antiviral drugs, has seen its SG&A expenses grow by approximately 104% over the past decade, peaking at $6.09 billion in 2023. This increase reflects Gilead's strategic investments in marketing and administration to maintain its market dominance.
Conversely, Travere Therapeutics, a smaller player focused on rare diseases, has experienced a more modest rise in SG&A expenses, increasing by around 345% to $265 million in 2023. This growth underscores Travere's expanding efforts to establish a foothold in the niche market of rare disease treatments.
This comparison highlights the contrasting strategies of these two companies in navigating the biotech landscape.
AstraZeneca PLC or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Incyte Corporation
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Pharming Group N.V.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Alkermes plc
Gilead Sciences, Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Gilead Sciences, Inc. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Regeneron Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Travere Therapeutics, Inc.
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Travere Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Perrigo Company plc and Travere Therapeutics, Inc.
Comparing SG&A Expenses: Arrowhead Pharmaceuticals, Inc. vs Travere Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Supernus Pharmaceuticals, Inc. and Travere Therapeutics, Inc.